MedTrace Logo

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

NCT02050594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2015-07-07

No results posted yet for this study

Summary

The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period

Conditions

Interventions

DRUG

Ipilimumab

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Venezuela

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02050594 on ClinicalTrials.gov